Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Opiant Pharmaceuticals, Inc. (OTC: OPNT).

Full DD Report for OPNT

You must become a subscriber to view this report.


Recent News from (OTC: OPNT)

FDA OKs first non-opioid treatment for opioid withdrawal
The FDA approves privately held US WorldMeds LLC's Lucemyra (lofexidine hydrochloride) for the management of opioid withdrawal symptoms in adults who abruptly discontinue opioids. More news on: Endo International plc, Allergan plc, Johnson & Johnson, Healthcare stocks news, Read ...
Source: SeekingAlpha
Date: May, 16 2018 16:44
Opiant Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results and Provides Corporate Update
SANTA MONICA, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today reported financial results for the first quarter ended March 31, 2018, a...
Source: GlobeNewswire
Date: May, 08 2018 16:05
Opiant Pharmaceuticals To Host Key Opinion Leader Meeting on Medications for Addictions and Related Disorders
Key Opinion Leader Luncheon to Take Place in New York City on May 10 SANTA MONICA, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, will host a Key Opi...
Source: GlobeNewswire
Date: May, 03 2018 08:00
Opioid prescriptions dropped 12% in 2017
Opioid prescriptions dropped 12% in 2017, according to a report from the IQVIA Institute for Human Data Science. More news on: Johnson & Johnson, Endo International plc, Teva Pharmaceutical Industries Limited, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: April, 26 2018 03:18
Blog Exposure - Opiant Pharma Receives Grant for Development of OPNT003 for Treatment of Opioid Overdose
Stock Monitor: ChannelAdvisor Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors.com has just released a free research report on Opiant Pharma, Inc. (NASDAQ: OPNT ) ("Opiant"). If you want access to this report all you need to do is sign up now by cli...
Source: ACCESSWIRE IA
Date: April, 20 2018 07:30
U.S. opioid prescriptions down 12% last year, largest drop in 25 years
According to IQVIA ( IQV -0.8% ), U.S. opioid prescriptions declined 12% in 2017, the largest annual drop in 25 years as doctors respond to the opioid crisis. More news on: IQVIA Holdings, Inc., Insys Therapeutics, Inc., Johnson & Johnson, Healthcare stocks news, News on ETFs, ...
Source: SeekingAlpha
Date: April, 19 2018 11:25
Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
Grant Expected to Fund Development of OPNT003 to NDA Ready Stage SANTA MONICA, Calif., April 18, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that...
Source: GlobeNewswire
Date: April, 18 2018 08:00
DEA aiming to collar production of opioids
The U.S. Drug Enforcement Administration (DEA) has unveiled plans to restrict the amount of opioids made by drug firms if it believes the medications are being diverted for illicit use. The proposed new rules were announced today in a speech by Attorney General Jeff Sessions. More news o...
Source: SeekingAlpha
Date: April, 17 2018 15:35
Sen. Sanders introduces bill to fine opioid makers for marketing practices
Reuters reports that U.S. Senator Bernie Sanders (I-VT) plans to introduce a bill today that would fine makers of opioid medications for deceptive marketing and implement harsh penalties for those found responsible for contributing to the drug epidemic. More news on: Insys Therapeutics, ...
Source: SeekingAlpha
Date: April, 17 2018 12:03
Will Opiant Pharma Solve The Biggest Crisis That The FDA Is Currently Facing?
In an interview with CNN on Thursday, Food and Drug Administration Commissioner Dr. Scott Gottlieb said that the opioid epidemic is still the biggest challenge that the FDA is currently facing. Last month, Trump administration announced a new plan to combat the epidemic by enactin...
Source: SeekingAlpha
Date: April, 11 2018 05:49

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-1416.3015.8216.7615.2118,079
2018-08-1315.5616.1217.1215.3525,487
2018-08-1016.2515.1117.2914.57981,103
2018-08-0919.0817.6019.4916.2556,112
2018-08-0816.8719.4519.5016.7577,344

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2017-08-2817,47724,52971.2504Short
2017-08-2514,66233,14544.2359Short
2017-08-243,80510,18637.3552Short
2017-08-236,90313,05952.8601Short
2017-08-2211,18816,01469.8639Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on OPNT.


About Opiant Pharmaceuticals, Inc. (OTC: OPNT)

Logo for Opiant Pharmaceuticals, Inc. (OTC: OPNT)

Opiant Pharmaceuticals is a specialty pharmaceutical company developing treatments for substance use, addictive and eating disorders.

 

 

 

Current Management

  • Roger Crystal / CEO, President
  • Kevin Pollack / CFO, Treasurer, Secretary
  • Michael Sinclair / Chairman, Executive Chairman
  • Roger Crystal /
  • Ann MacDougall / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Kevin Pollack /
  • Gabrielle Silver / Independent Director, Nominating Committee Member
  • Thomas T. Thomas / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Geoffrey Wolf / Independent Director, Audit Committee Member, Nominating Committee Member

Current Share Structure

  • Market Cap: $51,491,272 - 03/09/2018
  • Authorized: 200,000,000 - 03/01/2018
  • Issue and Outstanding: 2,537,766 - 03/01/2018

 


Recent Filings from (OTC: OPNT)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 18 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 17 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 17 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: April, 11 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: March, 19 2018
Annual transition reports filed under rule 13a-10 or 15d-10 of the Securities Exchange Act
Filing Type: 10-KTFiling Source: edgar
Filing Date: March, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 05 2018
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: February, 28 2018

 

 


Daily Technical Chart for (OTC: OPNT)

Daily Technical Chart for (OTC: OPNT)


Stay tuned for daily updates and more on (OTC: OPNT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: OPNT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in OPNT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of OPNT and does not buy, sell, or trade any shares of OPNT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/